/image%2F3334645%2F20201111%2Fob_fd07bb_sans-titre-1.jpg)
/image%2F3334645%2F20260815%2Fob_bc620d_776497617-2038408443455296-23321386311.jpg "What Makes Witch Hazel Effective? Science, Mechanisms, and Clinical Evidence")
/image%2F3334645%2F20260815%2Fob_0b61ff_1648b369-8789-4bda-ba8e-e0f14509b143.jpg "Witch Hazel and Its Health Benefits: What the Research Shows")
/image%2F3334645%2F20260813%2Fob_b43f9c_769309559-2140073886540951-57767507467.net%26_nc_cat%3D103%26_nc_ohc%3D4QRjV1Bt6mMQ7kNvwEXX8Hm%26sdl%3D0%26ccb%3D14-4%26oh%3D00_AQEewd55H0n7-7rqoPxlPHipVunD0UlbK_kX7bWw4GptTQ%26oe%3D6A840C87%26_nc_sid%3Da21977 "Theoretical Foundations of Cold Laser Water Imprinting")
/image%2F3334645%2F20260813%2Fob_c7a592_bdff188c-2305-4a08-bbd1-19ddd0b42cfe.jpg "Cold Laser-Based Water Imprinting: A Review of Exposure Duration and Proposed Mechanisms")
/image%2F3334645%2F20260812%2Fob_1114bb_aug-12-2026-03-02-57-pm.png "From Resonant Frequencies to Biological Effects: Experimental Extensions of the Resonant Recognition Model")
/image%2F3334645%2F20260810%2Fob_8634c6_oig1.yWdw_LTFGSh7hPhQqazw%3Fw%3D1024%26h%3D1024%26qlt%3D70%26p%3D0%26r%3D0%26o%3D4%26pid%3DImgGn "The Resonant Recognition Model: Searching for Hidden Frequencies in DNA and Proteins")
/image%2F3334645%2F20260806%2Fob_33a5c3_imefefzage-1-c.jpg "Soquelitinib: A Potential New Treatment for Inflammatory Diseases")
/image%2F3334645%2F20260805%2Fob_afeba9_766221654-1377354427854223-55085509030.net%26_nc_cat%3D107%26_nc_ohc%3Df91CASdi6pcQ7kNvwGY-dZI%26sdl%3D0%26ccb%3D14-4%26oh%3D00_AQGGIMtSjoq8bH-AjqOyCYJO-jCK3Ds3w2WAlVSahh6y0Q%26oe%3D6A796F59%26_nc_sid%3Da21977 "Deeper Molecular Signatures: Fluorescence, NMR, Terahertz, and Circularly Polarized Emission")
/image%2F3334645%2F20260804%2Fob_9e339a_763992749-1764300548032994-46344489975.jpg "Spectroscopic Fingerprinting of Molecules: Theory, Measurement, and Real-World Applications")
/image%2F3334645%2F20260802%2Fob_b5c418_f3795fe1-14d0-4417-bd7c-d91c613666b2.jpg "Alpha-Tocopherol and Skin Health: The Science Behind Vitamin E")
Tilrekimig : a new trispecific antibody shows promise in treating eczema
/image%2F3334645%2F20260330%2Fob_29a488_f1d1ac1d-c987-477c-a90c-4f1b3376201d.png)
Pfizer’s trispecific antibody shows promise in treating eczema :
The pharmaceutical giant announced its candidate, tilrekimig, significantly reduced eczema severity in clinical trials.
Pharmaceutical conglomerate Pfizer recently announced promising Phase II clinical trial results (NCT05995964) for its trispecific antibody product, tilrekimig. The monthly treatment targets Type 2 chronic inflammatory conditions and is also being investigated for its therapeutic effect in treating asthma and chronic obstructive pulmonary disease (COPD).
“The study has met its primary endpoint, demonstrating a statistically significant 75% improvement in the Eczema Area and Severity Index score from baseline [EASI-75],” a Pfizer spokesperson told BioXconomy. “The study demonstrated competitive efficacy and the placebo-adjusted percentage at week 16, with 51.9% for the middle-tested dose and 49.4% for the high-tested dose.”
The EASI score is a tool used by dermatologists that measures the surface area and general severity of atopic eczema. It considers several pathological features, including redness, thickness, and intensity of scratching.
Tilrekimig targets three essential proteins in the inflammatory process: interleukin-13 (IL-13), interleukin-4 (IL-4), and thymic stromal lymphopoietin (TSLP). IL-13 and IL-4 are signaling molecules used in Type 2 immune responses; their over-expression is highly associated with chronic inflammation and allergy. TSLP is a signaling protein expressed in the skin that drives T cell and mast cell activation in adaptive immunity.
The company’s public statement says tilrekimig requires a once-monthly subcutaneous injection. It claims the antibody binds its target proteins and reduces chronic inflammation without damaging healthy cells, significantly improving patient outcomes when compared to placebo.
“We are encouraged by the topline Phase II results for tilrekimig, which show that combining the potent inhibition of IL-4/13 and TSLP pathways has the potential to deliver improved efficacy over the standard of care for atopic dermatitis,” said Pfizer chief inflammation and immunology officer Mike Vincent.
“We plan to advance a broad clinical development program for tilrekimig, a potential first-in-class trispecific antibody in atopic dermatitis and other Th2-mediated inflammatory diseases including asthma and COPD.”
The clinical trial will continue with stages three and four of the Phase II trial. This will entail comparing a variety of doses of tilrekimig to other biologic treatments, a placebo, and ompekimig, an interleukin-targeting monoclonal antibody. The trispecific antibody is also being studied for its use in treating asthma (NCT06977581) and COPD (NCT07363694) in two separate clinical trials.
Pfizer claims that, so far, adverse events for tilrekimig are limited but include skin infections, tissue disorders, and skin reactions at the site of injection. Although its clinical data is yet to be published formally, the pharmaceutical giant appears optimistic.
“Detailed results from the Phase II study of tilrekimig will be submitted to a future medical meeting and a peer-reviewed journal,” stated the spokesperson. “Pfizer plans to share results from the ongoing portions of the study in the future, pending completion.”
(Source : BioXconomy)
